验证去势抵抗性前列腺癌患者的前列腺癌总疾病负担指数（TIBI-CaP）：TRUMPET 研究的数据。
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.
机构信息
Astellas Pharma, Inc., Northbrook, IL 60062, USA.
Health Policy Research Institute, University of California, Irvine, CA 90024, USA.
出版信息
Future Oncol. 2018 Mar;14(6):527-536. doi: 10.2217/fon-2017-0438. Epub 2018 Feb 8.
AIM
To validate the total illness burden index for prostate cancer (TIBI-CaP) in castration-resistant prostate cancer (CRPC) patients.
PATIENTS & METHODS: Baseline comorbidity scores collected using the TIBI-CaP were compared with the baseline patient-reported health-related quality of life using the SF-12v2 and FACT-P questionnaires in 302 patients enrolled in the Treatment Registry for Outcomes in CRPC Patients (TRUMPET).
RESULTS
Baseline TIBI-CaP scores were negatively correlated with all baseline SF-12v2 domain/composite (p < 0.001) and FACT-P subscale/total (p < 0.020) scores. There was a significant decreasing linear trend in SF12v2 and FACT-P scores over the categories based on TIBI-CaP quartiles of comorbidity burden (from 'least' to 'severe').
CONCLUSION
The TIBI-CaP is a valid measure of comorbidity burden in patients with CRPC in the real world.
目的
验证前列腺癌总疾病负担指数（TIBI-CaP）在去势抵抗性前列腺癌（CRPC）患者中的适用性。
患者与方法
在接受治疗的转移性去势抵抗性前列腺癌患者结局研究登记处（TRUMPET）中，共纳入 302 例患者，本研究比较了基线时使用 TIBI-CaP 收集的合并症评分与基线时使用 SF-12v2 和 FACT-P 问卷报告的健康相关生活质量。
结果
基线 TIBI-CaP 评分与所有基线 SF-12v2 领域/综合评分（p<0.001）和 FACT-P 亚量表/总分（p<0.020）呈负相关。基于 TIBI-CaP 合并症负担四分位数，SF12v2 和 FACT-P 评分呈显著线性递减趋势（从“最低”到“严重”）。
结论
TIBI-CaP 是真实世界中 CRPC 患者合并症负担的有效衡量指标。
Zotero 插件